<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03076385</url>
  </required_header>
  <id_info>
    <org_study_id>VAL-506440-P101</org_study_id>
    <secondary_id>2015-003452-48</secondary_id>
    <nct_id>NCT03076385</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of H10N8 Antigen mRNA in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will assess the safety, tolerability and immunogenicity of VAL-506440 in&#xD;
      healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Types, frequency, and severity of serious adverse events (SAE), adverse events of special interest (AESI), and adverse events considered related to study drug</measure>
    <time_frame>Through 13 months of study participation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of hemagglutinin inhibition (HAI) seroconversion measured by a neutralization assay in comparison with baseline samples</measure>
    <time_frame>Through 13 months of study participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of microneutralization seroconversion measured by a neutralization assay in comparison with baseline samples</measure>
    <time_frame>Through 13 months of study participation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>VAL-506440</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VAL-506440</intervention_name>
    <description>Escalating dose levels</description>
    <arm_group_label>VAL-506440</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion&#xD;
&#xD;
          -  Agrees to comply with the study procedures and provides written informed consent&#xD;
&#xD;
          -  18 to 64 years of age&#xD;
&#xD;
          -  Body mass index between 18 and 30 kg/m2&#xD;
&#xD;
          -  Negative urine pregnancy test at the Screening visit and the day of each vaccination.&#xD;
&#xD;
          -  Female subjects must either be of non-childbearing potential or use highly effective&#xD;
             methods of contraception from at least 2 months before the Screening Visit through 3&#xD;
             weeks post last vaccination&#xD;
&#xD;
          -  In good health based on medical history, physical examination, vital sign measurements&#xD;
             and laboratory safety tests performed prior to initial study vaccination&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          -  Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care&#xD;
&#xD;
          -  Administration of an investigational product within 45 days&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding, or plan to become pregnant during the study&#xD;
&#xD;
          -  Prior administration of investigational agent using formulations similar to VAL-506440&#xD;
&#xD;
          -  History of a serious reaction to prior influenza vaccinations&#xD;
&#xD;
          -  History of Guillain-Barr√© Syndrome within 6 weeks following a previous influenza&#xD;
             vaccine&#xD;
&#xD;
          -  Administration of any live attenuated vaccines within 4 weeks before enrollment,&#xD;
             inactive vaccines within 2 weeks before enrollment, or plans to any vaccine within the&#xD;
             vaccination period&#xD;
&#xD;
          -  Any known or suspected immunosuppressive condition, acquired or congenital, as&#xD;
             determined by history and/or physical examination&#xD;
&#xD;
          -  Any chronic administration of immunosuppressant or other immune-modifying drugs within&#xD;
             6 months prior to administration of study vaccine&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products within the 3 months&#xD;
             preceding the administration of the study vaccine or during the study.&#xD;
&#xD;
          -  Any acute disease at the time of enrollment&#xD;
&#xD;
          -  Any bleeding risk or thromboembolic event or any related medical history&#xD;
&#xD;
          -  Regular alcohol consumption &gt; 3 units/day, or current user of any illicit drugs, or&#xD;
             has a history of drug/alcohol abuse with 1 year of screening or has a positive urine&#xD;
             drug/alcohol test at screening&#xD;
&#xD;
          -  Persons employed in a capacity that involves handling poultry or wild birds&#xD;
&#xD;
          -  Unable to refrain from or anticipates the use of any medication, including&#xD;
             prescription and non-prescription drugs or herbal remedies within 4 weeks before&#xD;
             administration of the first vaccination, throughout the study&#xD;
&#xD;
          -  Had major surgery or donation of blood or blood products within 4 weeks of dosing&#xD;
&#xD;
          -  Current smoking of more than 10 cigarettes (or equivalent amount of tobacco) per day,&#xD;
             and within 3 months prior to Screening&#xD;
&#xD;
          -  Subject is an employee of the Sponsor or CRO involved in the study.&#xD;
&#xD;
          -  Vulnerable subjects (e.g., a subject kept in detention).&#xD;
&#xD;
          -  Any condition, that in the opinion of the Investigator would pose a health risk to the&#xD;
             subject if enrolled or could interfere with evaluation of the vaccine or&#xD;
             interpretation of the study results&#xD;
&#xD;
          -  History of autoimmune disease&#xD;
&#xD;
          -  Inadequate Liver Function as defined by AST, ALT, GGT, alkaline phosphatase and&#xD;
             bilirubin &gt; 1.5xULN&#xD;
&#xD;
          -  Known allergy or history of anaphylaxis or other serious adverse reactions to any of&#xD;
             the constituents of the study vaccine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 2, 2017</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2017</study_first_posted>
  <last_update_submitted>December 28, 2018</last_update_submitted>
  <last_update_submitted_qc>December 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VAL-506440</keyword>
  <keyword>H10N8 antigen mRNA</keyword>
  <keyword>Influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

